Digital Health & AI Trends (June 2026)
Click the cover to download report highlights
Enterprise EHR Foundation
Abridge is up this month with its strategy to excel at expanding value to health systems and connect them with payers and pharmas, using patient data in real time at the point of care. It is partnering with Eli Lilly on clinical trials and working with Nvidia on a new foundation model. Virtual nursing and smart patient rooms are up with Modern Healthcare reporting that AdventHealth, Houston Methodist, MetroHealth, and Virtua Health are pursuing similar objectives through different technology partners as smart rooms become a new standard for digitally enabled inpatient care.
Healthcare Analytics and Intelligence
AI models are great test takers with scores on most medical benchmarks in the 90s, and doing better than, for example, OpenEvidence and UpToDate, as well as real world physicians. But once the real language of physicians in texts replaces the academic, the LLMs get failing grades in the mid-40s. PowerScribe 360 with 75% of the radiology reporting market is discontinued by Microsoft which opens the segment for competitors such as Rad AI, Jacobian, Sectra, and Sirona.
Consumer Health and Technology
Patients are up this month, with new tools to give them control, like Kin Health's ambient scribe for patients, and $270m flooding into AI agents handling scheduling, navigation, and care access. Wearables are also up this month, with Rock Health reporting that 57% of US adults now own a device and 59% sharing their data with providers. Whole-body MRI is down with a JAMA editorial calling the category potentially harmful over-screening with no proven mortality benefit.
Stakeholders
ACA marketplace enrollment is down sharply as enhanced subsidies expire, with sign-ups falling 5% and analysts projecting five million fewer covered lives. 2027 looks to be worse still with Cigna among those already announcing exits. Drug shortages remain a systemic problem, with average duration now at 5.3 years and discontinuations jumping 60%. And a new EY report finds biotech revenue up to $232b with M&A rebounding to $100b, led by Eli Lilly's aggressive acquisition strategy, but the industry is shrinking as one-third of emerging companies have less than a year of cash remaining.